|196.64||+5.26||+2.75%||Vol 159.12K||1Y Perf -31.58%|
|Aug 11th, 2022 16:00 DELAYED|
|- -||7.36 3.74%|
|Target Price||288.67||Analyst Rating||Moderate Buy 1.75|
|Potential %||46.80||Finscreener Ranking||★★★+ 50.86|
|Insiders Trans % 3/6/12 mo.||-/-/-100||Value Ranking||★★ 46.98|
|Insiders Value % 3/6/12 mo.||-/-/-100||Growth Ranking||★★+ 49.77|
|Insiders Shares Cnt. % 3/6/12 mo.||-/-/-100||Income Ranking||— -|
|Price Range Ratio 52W %||25.44||Earnings Rating||Strong Buy|
|Market Cap||20.41B||Earnings Date||4th Aug 2022|
Today's Price Range
5 Year PE Ratio Range
|Moving Averages:||Strong Buy|
|Earnings History||Estimate||Reported||Surprise %|
|Earnings Per End||Estimate||Revision %||Trend|
|Next Report Date||-|
|Estimated EPS Next Report||-4.23|
|EPS Growth Next 5 Years %||-|
|Avg. Weekly Volume||225.33K|
|Avg. Monthly Volume||236.33K|
|Avg. Quarterly Volume||296.18K|
BeiGene Ltd. (NASDAQ: BGNE) stock closed at 196.64 per share at the end of the most recent trading day (a 2.75% change compared to the prior day closing price) with a volume of 159.12K shares and market capitalization of 20.41B. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 5300 people. BeiGene Ltd. CEO is John V. Oyler.
The one-year performance of BeiGene Ltd. stock is -31.58%, while year-to-date (YTD) performance is -27.42%. BGNE stock has a five-year performance of 176.88%. Its 52-week range is between 118.18 and 426.56, which gives BGNE stock a 52-week price range ratio of 25.44%
BeiGene Ltd. currently has a PE ratio of -8.80, a price-to-book (PB) ratio of 3.11, a price-to-sale (PS) ratio of 24.57, a price to cashflow ratio of 605.70, a PEG ratio of 2.32, a ROA of -28.32%, a ROC of -34.18% and a ROE of -39.61%. The company’s profit margin is -86.01%, its EBITDA margin is -216.50%, and its revenue ttm is $727.04 Million , which makes it $7.03 revenue per share.
Of the last four earnings reports from BeiGene Ltd., there were 2 positive earnings surprise and 2 negative earnings surprise. The company has EPS estimate of $-4.23 for the next earnings report. BeiGene Ltd.’s next earnings report date is -.
The consensus rating of Wall Street analysts for BeiGene Ltd. is Moderate Buy (1.75), with a target price of $288.67, which is +46.80% compared to the current price. The earnings rating for BeiGene Ltd. stock is Strong Buy (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).
BeiGene Ltd. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.
BeiGene Ltd. has a Buy technical analysis rating based on Technical Indicators (ADX : 16.89, ATR14 : 12.53, CCI20 : 133.34, Chaikin Money Flow : 0.01, MACD : 6.78, Money Flow Index : 51.58, ROC : 10.91, RSI : 49.71, STOCH (14,3) : 76.99, STOCH RSI : 0.85, UO : 57.70, Williams %R : -23.01), Simple Moving Averages and Exponential Moving Averages.
Aggregated Insider Trades of BeiGene Ltd. in the last 12-months were: John V. Oyler (Sold 347 803 shares of value $10 022 365 ), Lai Wang (Option Excercise at a value of $4 025 737)
Fri, 15 Jul 2022 16:47 GMT BeiGene (BGNE) Gets a Buy Rating from Morgan Stanley- TipRanks. All rights reserved.
Fri, 08 Jul 2022 02:48 GMT BeiGene (BGNE) Receives a Hold from SVB Securities- TipRanks. All rights reserved.
Mon, 28 Feb 2022 16:35 GMT Analysts Offer Insights on Healthcare Companies: BeiGene (BGNE), LHC Group (LHCG) and Natera (NTRA)- TipRanks. All rights reserved.
Tue, 18 Jan 2022 16:32 GMT BeiGene (BGNE) Receives a Buy from Morgan Stanley- TipRanks. All rights reserved.
Copyright © 2016-2022 Finscreener.org. All Rights Reserved.
Disclaimer: Before deciding to trade you should carefully consider your investment objectives, level of experience and your risk appetite. Forex and Tradegate data is a real-time with a 30 second refresh. Prices may not be accurate and may differ from the actual market price. Prices on the website are indicative and solely for informational purposes, not for trading purposes or advice. Please be aware of the risks associated with trading the on financial markets, it is one of the riskiest investment forms. Past performance does not guarantee future profits. We take no responsibility for any losses that may arise as a result of the data contained on this website. The content and the website are provided "as is", without any warranties. In no event will Finscreener.org, its employees, owners, directors, affiliates, partners, data provider, third party or anyone else liable to anyone else for any decision made regarding information on this website.
This could take some time, please wait.